20210310 Transgene TG4001 randomized Phase II EN
Category: TG4001
Correlation of HPV16 Gene Status and Gene Expression With Antibody Seropositivity and TIL Status in OPSCC
Adrian von Witzleben, et al. Front Oncol., January 26 2021 – Read the article Publication
Transgene to present Phase 1b/2 trial results of TG4001 in combination with avelumab in advanced HPV-positive cancers at ESMO IO 2020
20201203 – TG4001 mini oral prez ESMO IO EN
TG4001 (Tipapkinogene sovacivec) and avelumab for recurrent/metastatic (R/M) Human Papilloma Virus (HPV)-16+ cancers: clinical efficacy and immunogenicity
Poster SITC TG4001 C. Le Tourneau et al. SITC 2020 Download the poster here Poster Presentation
TG4001 (Tipapkinogene sovacivec) and avelumab for recurrent/metastatic (R/M) Human Papilloma Virus (HPV)-16+ cancers: clinical efficacy and immunogenicity
Poster SITC TG4001 C. Le Tourneau et al. SITC 2020 Download the poster here Poster Presentation
Transgene presents e-poster outlining detailed results from the Phase 1b/2 trial of TG4001 in combination with avelumab in advanced HPV-positive cancers at SITC 2020
20201109 – TG4001+avelumab presentation poster SITC – EN
Transgene announces detailed results from clinical study of TG4001 in combination with avelumab in advanced HPV-positive cancers
20201027 – TG4001+avelumab abstract data SITC – EN
Acceptance of Late Breaking Abstract at Upcoming SITC 2020 Conference, on the detailed results from clinical study of TG4001 in combination with avelumab in advanced HPV-positive cancers
20201019 TG4001+avelumab SITC – EN
Transgene Reports Results from Clinical Study of TG4001 in Combination with Avelumab in Advanced HPV-Positive Cancers
CP TG4001+avelumab EN – Vdef-
Phase Ib/II trial of TG4001 (Tipapkinogene sovacivec), a therapeutic HPV-vaccine, and Avelumab in patients with recurrent/metastatic HPV16 positive cancers
Christophe Le Tourneau et al. ESMO 2019 Download the poster here Poster Presentation